Cargando…
Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
SIMPLE SUMMARY: Regarded as the “disease that whispers” ovarian cancer remains difficult to diagnose and treat due to other complex conditions that may occur together. As research into new treatments for ovarian cancer continues, growing efforts to understand how treatments may be impact the day to...
Autores principales: | Bhat, Gita, Karakasis, Katherine, Oza, Amit M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694966/ https://www.ncbi.nlm.nih.gov/pubmed/33171791 http://dx.doi.org/10.3390/cancers12113296 |
Ejemplares similares
-
Ovarian cancer treatment: The end of empiricism?
por: Lheureux, Stephanie, et al.
Publicado: (2015) -
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
por: Colombo, Ilaria, et al.
Publicado: (2023) -
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020) -
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
por: Karakasis, Katherine, et al.
Publicado: (2016) -
Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)